Merck profit beats on strong demand for Keytruda, vaccines

Merck & Co Inc reported higher-than-expected second-quarter profit on Tuesday, powered by strong demand for its cancer immunotherapy Keytruda and vaccines, sending its shares up 3% in early trading.